Literature DB >> 2471652

Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation.

E Morra1, M Lazzarino, A Castello, D Inverardi, A Coci, G Pagnucco, E Orlandi, S Merante, U Magrini, G Zei.   

Abstract

In a series of 172 patients with non-Hodgkin's lymphoma (NHL) classified according to the Working Formulation (WF) the overall incidence of bone marrow infiltration (BM+) at diagnosis was 39%: 59% for low-grade (LGML), 30% for intermediate-grade (IGML), and 25% for high-grade malignant lymphomas (HGML). The features most significantly correlated with the presence of BM+ were a low grade of histological malignancy, the degree of splenomegaly and high values of LDH, while those correlated with the extent of BM+ were a non-focal pattern of BM disease, the presence of blood involvement at diagnosis, and the degree of BM fibrosis. Blood involvement was detected at diagnosis in 13% of patients, and a further 16% developed a leukemic phase during the course of the disease. Blood involvement correlated significantly with splenomegaly, bulky disease, advanced clinical stage, and extent of BM+. The presence of BM infiltration 'per se' at diagnosis did not significantly affect prognosis. However, the extent of BM disease was correlated with a poorer outcome in IGML and HGML patients. Regarding peripheral blood involvement, in LGML patients only late leukemic conversions were significantly associated with a worse prognosis. In patients with IGML and HGML, either initial or subsequent blood involvement was correlated with significantly poorer outcome.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471652     DOI: 10.1111/j.1600-0609.1989.tb01469.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase.

Authors:  Preetesh Jain; Rachel Lynn Sargent; Sergej N Konoplev; Ohad Benjamini; Hagop Kantarjian; Tapan Kadia
Journal:  Am J Hematol       Date:  2013-03-05       Impact factor: 10.047

2.  Lack of utility of CD20 immunohistochemistry in staging bone marrow biopsies for diffuse large B-cell lymphoma.

Authors:  Daniel Baiyee; Roger Warnke; Yasodha Natkunam
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-03

Review 3.  Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party.

Authors:  Yong Park; Byung Bae Park; Ji Yun Jeong; Wook Youn Kim; Seongsoo Jang; Bong Kyung Shin; Dong Soon Lee; Jae Ho Han; Chan-Jeoung Park; Cheolwon Suh; Insun Kim; Hyun-Sook Chi
Journal:  Korean J Intern Med       Date:  2016-11-01       Impact factor: 2.884

4.  Prognostic Value of Bone Marrow F-18 FDG Uptake in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma.

Authors:  Jiyoung Wang; Dongwoo Kim; Won Jun Kang; Hojin Cho
Journal:  Nucl Med Mol Imaging       Date:  2019-12-13

5.  FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.

Authors:  Dominic Kaddu-Mulindwa; Bettina Altmann; Viola Poeschel; Dirk Hellwig; Gerhard Held; Stephanie Angel; Stephan Stilgenbauer; Lorenz Thurner; Moritz Bewarder; Maren Schwier; Michael Pfreundschuh; Markus Löffler; Karin Menhart; Jirka Grosse; Marita Ziepert; Ken Herrmann; Ulrich Dührsen; Andreas Hüttmann; Francesco Barbato
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-29       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.